Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the transaction, the director owned 360,682 shares of the company’s stock, valued at $91,245,332.36. This represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ JAZZ opened at $256.65 on Friday. The firm has a market cap of $16.66 billion, a price-to-earnings ratio of 17.70, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company’s 50-day simple moving average is $240.89 and its 200-day simple moving average is $209.19. The company has a quick ratio of 1.85, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 52-week low of $106.65 and a 52-week high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The firm’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter last year, the company earned ($8.25) EPS. Equities analysts predict that Jazz Pharmaceuticals PLC will post 21.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. USA Financial Formulas purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. LRI Investments LLC purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $38,000. Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $40,000. Geneos Wealth Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on JAZZ shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $287.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday. Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a research note on Tuesday. Barclays raised their price objective on Jazz Pharmaceuticals from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Truist Financial set a $264.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $272.74.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo upgraded Jazz Pharmaceuticals to Buy and raised its price target to $300 from $285, adding to a broadly favorable analyst view. Jazz Pharmaceuticals Receives a Buy from Wells Fargo
• Positive Sentiment: Morgan Stanley raised its price target to $280, while Needham also forecast meaningful appreciation and maintained a bullish stance. JPMorgan separately indicated that the stock could rise, reinforcing investor confidence in JAZZ’s valuation and growth prospects. Morgan Stanley Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz’s second-quarter revenue reached $1.21 billion, exceeding the $1.11 billion consensus estimate and increasing 15.5% year over year. Management raised its 2026 revenue guidance to $4.60 billion-$4.75 billion, supported by strength in its neuroscience and oncology businesses.
• Positive Sentiment: The Xywav-led oxybate franchise continues to post double-digit growth despite generic Xyrem competition, reducing concerns about near-term erosion in Jazz’s core business. Potential FDA approval of Ziihera for first-line gastroesophageal cancer on August 25 also provides an additional catalyst.
• Neutral Sentiment: A valuation comparison with Techne highlights JAZZ as a stock investors are assessing on earnings, growth and relative value metrics, but the article does not represent a new fundamental development for Jazz Pharmaceuticals. JAZZ vs. TECH Which Stock Is the Better Value Option
• Negative Sentiment: Adjusted quarterly EPS of $5.71 missed the $6.18 consensus estimate, which could limit upside if future earnings do not keep pace with revenue growth.
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares worth about $1.52 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by only 1.64%, making it a limited signal of insider concern.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.